This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when continued under the same regimen as in the parent study.
To be eligible for this rollover study, participants must be continuing to benefit from their treatment, show an acceptable safety profile, and not have access to commercially available comparator anticancer therapy. Once transitioned to this study, participants will continue with their next planned dose per the regimen of their parent study.

Start Date04 Dec 2025

Sponsor / Collaborator

Ryvu Therapeutics SA

NCT06397313

/ TerminatedPhase 2

An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination With Ruxolitinib in Patients With Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)

The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.

Start Date19 Sep 2024

Sponsor / Collaborator

Ryvu Therapeutics SA

NCT06243458

/ RecruitingPhase 2

A Phase II, Open-label, Multicenter Study of Orally Administered RVU120 for the Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (MDS)

This study will evaluate orally administered RVU120, a novel small molecule Cyclin-dependent Kinase (CDK) 8/19 inhibitor, in terms of erythroid hematologic improvement (HI-E) and safety in participants with lower-risk myelodysplastic syndrome (MDS). Responding patients are eligible to continue treatment until loss of response/disease progression.

Start Date10 Sep 2024

Sponsor / Collaborator

GCP Service International Ltd & Co KG

[+6]

100 Clinical Results associated with SEL-120

100 Translational Medicine associated with SEL-120

100 Patents (Medical) associated with SEL-120

Literatures (Medical) associated with SEL-120

01 Jul 2025·BIOCHEMICAL PHARMACOLOGY

Identification of pyrazole scaffold inhibitors targeting cyclin-dependent kinase 8 for potential use in pulmonary fibrosis

Article

Author: Yen, Shih-Chung ; Sung, Tzu-Ying ; Yang, Chia-Ron ; Chang, Yu-Wei ; Hsu, Jui-Yi ; Tsai, En-Yun ; Wu, Yi-Wen ; Hsu, Kai-Cheng ; Huang, Wei-Jan ; Pan, Shiow-Lin ; Hsieh, Jui-Hua ; Chou, Ching-Hsuan ; Lin, Tony Eight

Idiopathic Pulmonary Fibrosis (IPF) is a disease that includes inflammation and scarring of the lung tissues. Cyclin-dependent kinase 8 (CDK8) is a target of interest due to its role in inflammatory pathways. CDK8 can also modulate the TGF-β/Smad signaling associated with IPF. Herein, a structure-based virtual screening (SBVS) campaign led to the identification of three CDK8 inhibitors. Testing of candidate inhibitors in protein and cellular assays confirmed CDK8 inhibition, with the most potent inhibitor producing an IC₅₀ value of 398.8 nM. Computational analysis identified pharmacological interactions that lead to CDK8 inhibition. No significant cytotoxicity was observed when the inhibitor was treated in vitro. Further results showed that the inhibitor can disrupt proteins associated with the epithelial-mesenchymal transition (EMT) and reduce cell migration. Additionally, the inhibitor can disrupt the TGF- β1/Smad signaling axis in the nucleus, potentially impacting the transcription of IPF related protein expression, when treated in cells at 5 µM. Comparisons to structures of known CDK8 inhibitors showed the identified inhibitor to be structurally novel. When tested against a panel of kinases at 1 µM, the most potent inhibitor demonstrated a favorable CDK8 selectivity profile. The identification of the CDK8 inhibitors in this study can be used in future drug design studies and as CDK8 probes to explore alternative therapeutics for IPF.

01 Jun 2024·PROTEIN SCIENCE

An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors

Article

Author: Jui‐Yi Hsu ; Tony Eight Lin ; Shih‐Chung Yen ; Dyan Yen ; Shiow‐Lin Pan ; Kai‐Cheng Hsu ; Yi‐Wen Wu ; Wei‐Jan Huang ; Wei‐Chun HuangFu ; Jui‐Hua Hsieh ; Tzu‐Ying Sung ; Chia‐Ron Yang

Abstract:

The identification of an effective inhibitor is an important starting step in drug development. Unfortunately, many issues such as the characterization of protein binding sites, the screening library, materials for assays, etc., make drug screening a difficult proposition. As the size of screening libraries increases, more resources will be inefficiently consumed. Thus, new strategies are needed to preprocess and focus a screening library towards a targeted protein. Herein, we report an ensemble machine learning (ML) model to generate a CDK8‐focused screening library. The ensemble model consists of six different algorithms optimized for CDK8 inhibitor classification. The models were trained using a CDK8‐specific fragment library along with molecules containing CDK8 activity. The optimized ensemble model processed a commercial library containing 1.6 million molecules. This resulted in a CDK8‐focused screening library containing 1,672 molecules, a reduction of more than 99.90%. The CDK8‐focused library was then subjected to molecular docking, and 25 candidate compounds were selected. Enzymatic assays confirmed six CDK8 inhibitors, with one compound producing an IC50 value of ≤100 nM. Analysis of the ensemble ML model reveals the role of the CDK8 fragment library during training. Structural analysis of molecules reveals the hit compounds to be structurally novel CDK8 inhibitors. Together, the results highlight a pipeline for curating a focused library for a specific protein target, such as CDK8.

11 Nov 2021·ACS medicinal chemistry lettersQ3 · MEDICINE

Development of Highly Potent and Selective Pyrazolopyridine Inhibitor of CDK8/19

Q3 · MEDICINE

Article

Author: Gray, Nathanael S. ; Wang, Eric ; Jiang, Jie ; Vatsan, Prasanna S. ; Hatcher, John M.

CDK8 and its paralog CDK19 are cyclin-dependent kinases that are core components of the so-called Mediator complex that has essential roles as a positive and negative regulator of gene expression. Several efforts to develop inhibitors have yielded natural and synthetic ATP-competitive compounds including cortistatin A, Sel120, BCD-115, CCT251921 (1), and MSC2530818 (2). Here, we used a hybridization approach starting from CCT251921 and MSC2530818 to derive new inhibitors with the aim of developing highly potent and selective inhibitors of CDK8/19. Initial compounds suffered from rapid aldehyde oxidase-mediated metabolism. This liability was overcome by utilizing a pyrazolopyridine hinge binder with a chlorine at the C-3 position. These efforts resulted in JH-XVI-178 (compound 15), a highly potent and selective inhibitor of CDK8/19 that displays low clearance and moderate oral pharmacokinetic properties.

News (Medical) associated with SEL-120

25 Aug 2026

·allsci.com

CDK8 emerges as potential disease-modifying target in osteoarthritis

Inhibiting a transcriptional kinase already explored in oncology can suppress the pathological cellular transition associated with cartilage breakdown in osteoarthritis (OA), according to preclinical findings published in Bone Research. The study, led by Scott J. Roberts at the Royal Veterinary College (RVC) in London, UK, provides in vivo evidence that cyclin-dependent kinase 8 (CDK8) inhibition can modulate processes involved in endochondral ossification and OA, reducing cartilage pathology in a spontaneous mouse model while affecting cartilage, bone, and inflammatory pathways. OA affects hundreds of millions of people worldwide, yet no disease-modifying OA drug (DMOAD) has reached the market. As the paper's authors note, "despite OA being the commonest form of arthritis, there are no disease-modifying therapeutics and clinical development of single-target approaches, including IL-1β and ADAMTS5, has failed despite promising data from preclinical models." CDK8, a kinase subunit of the Mediator transcriptional complex, was elevated in chondrocytes from human OA cartilage (Mankin scores 5–10) compared with non-lesion tissue, and lentiviral overexpression of CDK8 in chondrocyte models recapitulated pro-degenerative transcriptional signatures — supporting a functional rather than merely correlative role. The central mechanism involves CDK8's phosphorylation of STAT1 at serine-727 and its regulation of downstream Wnt, TGF-β, BMP, and NF-κB pathways, all of which govern chondrocyte differentiation state. In healthy articular cartilage, chondrocytes maintain a stable, non-hypertrophic phenotype; in OA, they aberrantly transition toward hypertrophy — upregulating mineralization markers and degradative enzymes while losing matrix-producing capacity. CDK8 inhibition, the authors propose, acts as a transcriptional rheostat that stabilizes the non-hypertrophic state by suppressing this axis. The in vivo component used male STR/Ort mice, a spontaneous OA model, dosed orally with 5 mg/kg of the selective CDK8/19 inhibitor MSC2530818 (MSC-818; biochemical IC₅₀ = 2.5 nmol/L) three times per week for 12 weeks, beginning at 22 weeks of age. Treated animals (n = 12 limbs from 6 mice) showed reduced Osteoarthritis Research Society International (OARSI) histological scores compared with vehicle-treated controls (n = 10 limbs from 5 mice), indicating attenuated cartilage degradation. Complementary matrix integrity scoring and Masson's Trichrome staining supported preservation of collagen architecture. Micro-computed tomography analysis showed reduced growth plate bridge number and areal density, particularly in the lateral compartment. Treadmill-based gait analysis indicated functional differences in treated animals consistent with reduced joint pathology. No overt toxicity was observed over the 12-week dosing period, though the study was not designed for formal safety profiling. In vitro, the chondroprotective effects were validated across multiple structurally distinct CDK8 inhibitor series, reducing the likelihood that findings reflect off-target compound activity. Bulk RNA sequencing identified downregulation of NF-κB and JAK-STAT inflammatory pathways and upregulation of extracellular matrix organization programs. Seahorse metabolic profiling indicated that CDK8 inhibition shifted chondrocytes away from glycolysis-dominant metabolism toward preserved oxidative phosphorylation capacity — a metabolic profile associated with healthier chondrocyte function. Effects were directionally consistent across primary equine articular chondrocytes from six donors and in THP-1-derived macrophages, where CDK8 inhibition reduced phospho-STAT1 and pro-inflammatory cytokine expression. A parallel 2025 publication reported that CDK8 promotes OA pathology via an NF-κB/senescence-associated secretory phenotype (SASP) axis — a distinct mechanistic angle that independently corroborates CDK8's relevance as an OA target. No CDK8 inhibitor has entered clinical development for any musculoskeletal indication. In oncology, the most clinically advanced agent in this class is romaciclib (RVU120), developed by Poland-based Ryvu Therapeutics, which is currently in Phase II trials for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, including the RIVER-81 study (NCT06191263). Other molecules include Biocad's BCD-115 (Senexin B), a selective CDK8/19 inhibitor. SEL120-34A, the same compound as romaciclib, was among the CDK8 inhibitors screened in the paper's in vitro chondrocyte platform. MSC-818 itself has not entered clinical trials in any indication and remains a research-stage tool compound. Biosplice Therapeutics submitted an NDA to the FDA in January 2026 for lorecivivint, a CLK2/DYRK1A inhibitor that modulates Wnt signaling via alternative splicing and is administered by intra-articular injection — described at submission as the first DMOAD candidate ever filed for FDA approval, though no approval has been confirmed as of the current date. Sprifermin, a recombinant FGF18 developed by Merck KGaA in collaboration with Nordic Bioscience, completed Phase II with five-year cartilage thickness benefit in the FORWARD study; no confirmed active Phase III trial has been identified. The authors describe CDK8/19 inhibition as "a promising disease-modifying strategy for targeting whole-joint disease in OA," citing its simultaneous effects across cartilage, bone, and inflammatory cell types. The study was conducted by a consortium spanning the RVC, University College London, Middlesex University, the Institute of Cancer Research, and the University of Oxford, with human cartilage sections provided by Erasmus MC in Rotterdam. Authors Wells and Roberts disclosed a patent application (WO2023/237861) relating to CDK8/19 inhibitor development. Spot something wrong? Report an issue with this article

Phase 2Clinical ResultPhase 3NDA

11 Jun 2026

·ryvu.com

Ryvu Therapeutics presents clinical data and program update on romaciclib at the European Hematology Association Congress 2026

Romaciclib in acute myeloid leukemia (AML): In the RIVER-81 Phase II study, romaciclib combined with venetoclax (VEN) shows encouraging anti-leukemic activity, including durable responses, in patients with relapsed/refractory AML (r/r AML) after VEN-based therapy failure. These results support further clinical development at the selected dose. On May 28, 2026, the Food and Drug Administration (FDA) reactivated the IND, enabling the initiation of the expansion cohort at the recommended dose of 150 mg once daily (QD). Romaciclib in myelofibrosis (MF): In the POTAMI-61 Phase II study, romaciclib demonstrates a favorable safety profile and clinical activity in myelofibrosis (MF), both as monotherapy and in combination with ruxolitinib (RUX). The observed spleen volume reductions and hematologic tolerability support continued clinical evaluation. Eight patients from POTAMI-61 will continue treatment in the ROVER-01 study, reflecting ongoing clinical benefit in a subset of patients. Krakow, Poland – June 11, 2026 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, presents romaciclib (RVU120) data at the European Hematology Association Congress (EHA), June 11-14, 2026, in Stockholm, Sweden. Hendrik Nogai, M.D., Chief Medical Officer of Ryvu Therapeutics said: We are pleased to share updated clinical data at EHA that reinforce the potential of romaciclib across hematologic malignancies. The poster presentations highlight consistent clinical activity and a manageable safety profile, both as a single agent and in rational combinations, including in difficult-to-treat patient populations. Importantly, the FDA review of the program and the recent reactivation of the RIVER-81 IND in the US as well as the continued treatment of patients from POTAMI-61 in the ROVER-01 study, are meaningful signals reflecting both regulatory progress and continued patient benefit. These milestones strengthen our confidence in romaciclib’s differentiated mechanism of action and support its continued clinical advancement. Program updates: In the RIVER-81 trial of patients with r/r AML, Ryvu is initiating an expansion cohort of approximately 30 patients to confirm the positive efficacy demonstrated in the dose cohort of 150 mg QD romaciclib combined with 400 mg QD venetoclax. Following completion of the required regulatory steps, including an updated study protocol and submission of documentation under the existing IND, the FDA reactivated the IND for RIVER-81 study on May 28, 2026. In the POTAMI-61 study investigating romaciclib’s efficacy in MF, eight patients will be transferred into the ROVER-01 study rollover protocol, underscoring that a subset of patients continue to derive meaningful clinical benefit from romaciclib treatment. These patients will continue to receive treatment with romaciclib as long as they benefit in ROVER-01. EHA poster presentations: Poster (PF529):  Updated findings from the Phase 2 RIVER-81 study of romaciclib (RVU120) combined with venetoclax in acute myeloid leukemia after first-line venetoclax and hypomethylating agent failure Poster session date and time: Friday, June 12 (6:45 – 7:45 PM CEST) Venetoclax (VEN) combined with hypomethylating agents is the standard first-line treatment for patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy, yet ~70% experience relapsed/refractory disease with a median survival of under three months. Romaciclib, a first-in-class CDK8/CDK19 inhibitor, has shown single-agent activity in AML and preclinical synergy with VEN through enhanced apoptotic signaling and attenuation of resistance pathways. In the ongoing Phase 2 RIVER-81 trial, romaciclib in combination with VEN demonstrates anti-leukemic activity in patients with poor prognostic AML. While responses have been observed across dose levels, the most consistent responses were seen at romaciclib 150 mg QD + VEN 400 mg QD, including two complete remissions with (CR) and one without (CRi) full hematologic recovery, resulting in a CR/CRi rate of 43% (3/7). The mean duration of response (DoR) of the CRs was 156 days, reported with a cut-off date of 12 May 2026. Based on safety, PK, and preliminary efficacy findings, this regimen was selected as the recommended dose for expansion. Poster (PS2008):   Romaciclib (RVU120), a selective CDK8/19 inhibitor, as monotherapy or in combination with ruxolitinib in patients with myelofibrosis: Updated results from the phase II POTAMI-61 study Poster session date and time: Saturday, June 13 (6:45 – 7:45 PM CEST) Myelofibrosis (MF) is driven by dysregulated JAK/STAT signaling, and while JAK inhibition with ruxolitinib (RUX) improves splenomegaly and symptoms, cytopenias and suboptimal responses remain clinical challenges. Romaciclib is a first-in-class, oral CDK8/19 inhibitor that modulates STAT-dependent transcription and shows synergy with RUX in preclinical MF models. In the ongoing Phase II POTAMI-61 study, romaciclib administered as monotherapy or combined with RUX demonstrates a manageable safety profile in patients with MF without significant treatment-related cytopenias. Prolonged exposure, spleen volume reductions, including in patients with high-molecular-risk mutations, and favorable hematologic tolerability support continued clinical development. The posters are available online and can be accessed via the conference website:  https://ehaweb.org/ and Ryvu’s website: https://ryvu.com/ The project entitled “The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent.”, carried out by Ryvu Therapeutics S.A., is co-financed by the Medical Research Agency from the state budget under the “Development of targeted or personalised medicine based on medicinal products involving nucleic acids and small-molecule compounds” call (ABM/2022/6). Total Project value: PLN 132,471,740.70 Total funding: PLN 62,268,848.90 RYVU Therapeutics Leona Henryka Sternbacha 2 30-394 Kraków, Poland

Phase 2Clinical ResultASHIND

21 May 2026

·ryvu.com

Ryvu Therapeutics reports first quarter 2026 financial results and provides corporate update

Following an analysis of Company resources and positive data in r/r AML, a population of high unmet medical need, Ryvu is prioritizing rapid development of romaciclib in AML. Updated clinical data from the Phase II RIVER-81 and POTAMI-61 studies will be presented at EHA 2026 (June 11-14, Stockholm). The Company signed the PERO grant agreement with the National Centre for Research and Development (NCBR), securing PLN 20.0 million in non-dilutive funding for an innovative oncology target validation platform. Total operating revenues in Q1 2026 amounted to €5.1 million, compared to €5.0 million for the same period in 2025. EBITDA loss was €2.4 million, compared to €8.4 million in the previous year. As of May 15, 2026, Ryvu’s cash position was €17.6 million. The Company has also secured approximately €20.6 million in non-dilutive grant funding. Krakow, Poland – May 21, 2026 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today reported financial results for the first quarter, ended March 31, 2026. Pawel Przewiezlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics, said: Clinical results in RIVER-81 and POTAMI-61 Phase II studies support romaciclib’s further development both in acute myeloid leukemia and myelofibrosis. Based on resources and clinical data generated so far, we decided to prioritize the AML development path by enrolling approximately 30 additional patients in RIVER-81. Alongside romaciclib clinical development, we have demonstrated good results in our early-stage programs, including RVU305, our potentially best-in-class MTA-cooperative PRMT5 inhibitor and ONCO Prime platform. Projects developed in cooperation with our partners are progressing, with potentially important milestones ahead. Q1 2026 SUMMARY AND RECENT CORPORATE EVENTS Romaciclib (RVU120) clinical development plan progress Ryvu continues to advance the clinical development of romaciclib, a first-in-class selective CDK8/CDK19 inhibitor, across hematologic malignancies. Current data support continued development of romaciclib in acute myeloid leukemia (AML) and myelofibrosis (MF). With the particularly strong data in relapsed/refractory (r/r) AML, near-term priorities will focus on development in AML, where the high unmet medical need could lead to an accelerated approval path. Ryvu generated further clinical insights and will present updated clinical data from the RIVER-81 and POTAMI-61 studies at the European Hematology Association (EHA) Congress 2026 (June 11-14, Stockholm, Sweden). Based on available abstracts: RIVER-81: Romaciclib combined with venetoclax (VEN) shows encouraging anti-leukemic activity, including durable responses, in patients with r/r AML after VEN-based therapy failure. These results support further clinical development at the selected dose. POTAMI-61: Romaciclib demonstrates a favorable safety profile and clinical activity in MF, both as monotherapy and in combination with ruxolitinib. The observed spleen volume reductions and hematologic tolerability support continued clinical evaluation. On May 20, following the analysis of resources and clinical data generated so far, Ryvu decided to prioritize RIVER-81 study by enrolling approximately 30 additional patients. As part of resource prioritization, the Company decided to close the POTAMI-61 study (ongoing patients will continue to receive treatment in a new roll-over study ROVER-01). Ryvu retains the option to resume a modified MF development program. This approach is intended to preserve strategic optionality for romaciclib while, in the short term, focusing resources on the clinical dataset that is expected to be most relevant for potential development partners. New preclinical data for the ONCO Prime platform were presented at the AACR Annual Meeting 2026. Ryvu’s integrated precision oncology discovery platform leveraging patient-driven models, engineered systems, and high-throughput CRISPR/omics analytics, enables the identification of novel synthetic lethal vulnerabilities in genetically stratified colorectal cancer models, including proof-of-concept validation using a clinically approved drug. This establishes a scalable platform for drug discovery programs and strategic partnerships built on ONCO Prime’s ability to bridge functional genomics with therapeutic development. Extension of the research collaboration with BioNTech: on March 16, 2026, Ryvu reported that it amended its research collaboration and exclusive license option agreement with BioNTech, originally disclosed in November 2022. Under the amendment, the parties agreed to extend their research collaboration by an additional period of one year until November 2028. Grant funding for the PERO project: on March 11, 2026, the Company signed a grant agreement with the National Centre for Research and Development (in Polish: Narodowe Centrum Badań i Rozwoju; NCBR) for the PERO (“Predictive Engineering for Rational Oncology”) project. The objective of PERO is to establish an innovative technological platform for the functional validation of structural protein pockets of potential therapeutic targets in oncology. The project addresses a significant technological gap by enabling an in-depth, currently unavailable level of functional target validation based on integrated genomic, structural, and pharmacological data. The funding, PLN 20.0 million of a PLN 32.4 million project, will significantly fund the development of an innovative platform for functional target validation in oncology. Ryvu continues to advance partnerships with Menarini Group, BioNTech, and Exelixis, under which the Company is fully reimbursed for its expenses and has the potential to receive multiple financial milestones. KEY UPCOMING INDUSTRY AND INVESTOR EVENTS Ryvu will host partnering and investor meetings at the following conferences: ASCO Annual Meeting (Chicago, IL), May 29 to June 2 EHA Annual Congress (Stockholm, Sweden), June 12-15 BIO International Convention (San Diego, CA), June 22-25 Q1 2026 FINANCIAL UPDATE Cash Position – On May 15, 2026, Ryvu Therapeutics held €17.6 million in cash, cash equivalents and investment funds. In addition, the Company has secured approximately €20.6 million in non-dilutive grant funding. Operating Revenues – In Q1 2026, Ryvu recognized total operating revenues (including grants) of €5.1 million, compared with €5.0 million in Q1 2025. Operating costs, related primarily to research and development expenditures, excluding the valuation of NodThera shares and non-cash cost of valuation of the Incentive Program for Q1 2026, amounted to €8.0 million, compared to €11.4 million in Q1 2025. EBITDA result – EBITDA loss in Q1 2026 was €2.4 million, compared to €8.4 million in the previous year. Net Loss Attributable to Common Shareholders – In Q1 2026, the net loss attributable to common shareholders, excluding the non-cash cost of the Incentive Program, amounted to €2.9 million, compared to €5.8 million in the same period of the previous year. RYVU Therapeutics Leona Henryka Sternbacha 2 30-394 Kraków, Poland

License out/inPhase 2Financial StatementASHAACR

100 Deals associated with SEL-120

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myelofibrosis	Phase 2	Italy	Ryvu Therapeutics SA	19 Sep 2024
Myelofibrosis	Phase 2	Poland	Ryvu Therapeutics SA	19 Sep 2024
Chromosome 5q Deletion Syndrome	Phase 2	France	Ryvu Therapeutics SA	10 Sep 2024
Chromosome 5q Deletion Syndrome	Phase 2	Germany	Ryvu Therapeutics SA	10 Sep 2024
Chromosome 5q Deletion Syndrome	Phase 2	Italy	Ryvu Therapeutics SA	10 Sep 2024
Chromosome 5q Deletion Syndrome	Phase 2	Poland	Ryvu Therapeutics SA	10 Sep 2024
Chromosome 5q Deletion Syndrome	Phase 2	Spain	Ryvu Therapeutics SA	10 Sep 2024
Monosomy 7 of Bone Marrow	Phase 2	France	Ryvu Therapeutics SA	10 Sep 2024
Monosomy 7 of Bone Marrow	Phase 2	Germany	Ryvu Therapeutics SA	10 Sep 2024
Monosomy 7 of Bone Marrow	Phase 2	Italy	Ryvu Therapeutics SA	10 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06397313 (POTAMI-61, ASH2025)	Phase 1/2	Myelofibrosis	23	Romaciclib	sdgrfbayqf(hyqjlejpso) = jaiosnobzv bfsxgworff (vahkurubxe ) View more	Positive	06 Dec 2025
NCT06397313 (POTAMI-61, ASH2025)	Phase 1/2	Myelofibrosis	23	Romaciclib + Ruxolitinib	sdgrfbayqf(hyqjlejpso) = zmobcswjmg bfsxgworff (vahkurubxe ) View more	Positive	06 Dec 2025
NCT06191263 (REMARK, ASH2025)	Phase 2	Anemia \| Myelodysplastic-Myeloproliferative Diseases SF3B1 mutation	42	Romaciclib 150 mg q.o.d.	hzgluhhdgk(ujazovinqo) = nbezujliyf oiqzfhtncj (qotusqvyji ) View more	Positive	06 Dec 2025
NCT06191263 (RIVER-81, EHA2025)	Phase 2	Acute Myeloid Leukemia First line ASXL1 \| TP53 \| NRAS	36	RVU120+VEN	vwnkvbaids(pfynlcmutg) = 41% of the treated patients hnjnhvslla (jynipuufpn ) View more	Positive	14 May 2025
NCT06191263 (RIVER-81, EHA2025)	Phase 2	Acute Myeloid Leukemia First line ASXL1 \| TP53 \| NRAS	36	Placebo		Positive	14 May 2025
NCT04021368 (RIVER-52, EHA2025)	Phase 1	Acute Myeloid Leukemia \| Refractory High Risk Myelodysplastic Syndrome NPM1 mutation	39	RVU120 250 mg	imdfpcursc(eufqhjiakf) = Infectious complications were among the most frequent events uoianlregb (uzzepjyxxn ) View more	Negative	14 May 2025
NCT04021368 \| NCT06268574 (CLI120-001, EHA 12024 \| EHA 22024) Manual	Phase 1/2	High Risk Myelodysplastic Syndrome \| Refractory acute myeloid leukemia	39	RVU120	qfxexcghej(dmdpbqdxao) = In CLI120-001, Nausea and vomiting (mostly G1-2) were the most frequent treatment-emergent adverse events. In RIVER-52 did not experience any drug-related adverse events in the first cycle zllkecygtm (oamijlppzy ) View more	Positive	14 May 2024
NCT06191263 (RIVER-81, EHA 12024 \| EHA 22024) Manual	Phase 2	Acute Myeloid Leukemia Second line	3	RVU120+venetoclax	iwgarezyvt(nrrzrueffq) = None aiopcbsqdk (elbnxssdez ) View more	Positive	14 May 2024
NCT04021368 \| NCT06268574 (EHA2024)	Not Applicable	Myelodysplastic-Myeloproliferative Diseases Second line	39	RVU120	ljyhyxbuvp(ewanwbnjse) = hscdcyhais poefjqucoc (swfprcwkjj )	Positive	14 May 2024
NCT04021368 (CLI120-001, Biospace) Manual	Phase 1	Acute Myeloid Leukemia \| High Risk Myelodysplastic Syndrome	38	RVU120 250 mg	dlkcqpjhfs(rgnziyevpi) = mhtuewdulk drxwuhuado (pislhlfeex ) View more	Positive	11 Dec 2023
NCT05052255 (ESMO 12023 \| ESMO 22023) Manual	Phase 1/2	Solid tumor	30	RVU120	rrqryrnivo(gftrwyogel) = sbyhvvjugz kdgdnfrbef (ctmchnjroz ) View more	Positive	23 Oct 2023
NCT04021368 (CLI120-001, EHA2023)	Phase 1	High Risk Myelodysplastic Syndrome \| Refractory acute myeloid leukemia	22	RVU120	qttohuabmq(aqfdtijlrc) = in a patient treated at 100 mg sgvxdqbyxl (caiznurfif ) View more	-	08 Jun 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis